Skip to main content
Kexing Biopharm logo

Kexing Biopharm — Investor Relations & Filings

Ticker · 688136 ISIN · CNE100006ZG6 LEI · 529900Z34Q1M9A907771 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 756 across all filing types
Latest filing 2026-06-07 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688136

About Kexing Biopharm

https://www.kexingbiopharm.com/

Kexing Biopharm is an innovative biopharmaceutical enterprise engaged in the research, development, production, and sales of recombinant protein drugs and micro-ecological preparations. The company focuses on developing treatments for therapeutic areas including kidney diseases, oncology, antiviral therapy, autoimmune disorders, metabolic diseases, and degenerative diseases. A key product in its portfolio is Erythropoietin Injection. Kexing Biopharm maintains a comprehensive quality system that aligns with international standards, covering the entire drug lifecycle from production and quality control to release and transportation, ensuring the continuous and stable manufacturing of safe and effective medicines.

Recent filings

Filing Released Lang Actions
北京市嘉源律师事务所关于科兴生物制药股份有限公司差异化分红事项的法律意见书
Regulatory Filings Classification · 85% confidence The document is a legal opinion letter issued by a law firm regarding the legality and compliance of a differentiated dividend distribution plan under relevant company and securities laws. It does not present financial statements (so it is not an annual or interim report), nor is it an earnings release, proxy statement, director dealing report, or dividend notice from the company itself. Instead, it is a compliance/legal submission accompanying corporate actions. Therefore it fits the “Regulatory Filings” category (RNS) as a general regulatory announcement/compliance document.
2026-06-07 Chinese
2025年年度权益分派实施公告
Notice of Dividend Amount Classification · 95% confidence The document is an announcement by 科兴生物制药股份有限公司 regarding the implementation of the 2025 annual profit distribution (dividend) plan, including the per-share cash dividend amount, record date, ex-dividend date, payment date, and tax withholding details. It does not contain full financial statements or broader reporting content, but focuses solely on dividend distribution specifics. This matches the definition of a Notice of Dividend Amount (DIV).
2026-06-07 Chinese
Update zu innovativem Arzneimittel | Kexing Biopharm nimmt ersten Studienteilnehmer in die in China durchgefuhrte klinische Phase-I-Studie mit dem innovativen ophthalmologischen Arzneimittel GB10 auf
Regulatory Filings Classification · 85% confidence The document is a press release/corporate news update announcing the initiation of a Phase I clinical study for a new ophthalmological drug. It contains no financial results, no reference to an AGM or shareholder vote, no capital changes, no legal proceedings, and no detailed financial statements. It is a general corporate announcement distributed via EQS, fitting the ‘Regulatory Filings’ (RNS) fallback category for miscellaneous corporate news. It is not a report itself, nor a mere ‘Report Publication Announcement,’ but a routine regulatory news disclosure.
2026-06-05 German
Innovative Drug Update | Kexing Biopharm Enrolls First Subject in China-based Phase I Clinical Trial of Ophthalmic Innovative Drug GB10
Regulatory Filings Classification · 45% confidence The document is a corporate press release detailing the enrollment of the first subject in a Phase I clinical trial for an innovative drug. It contains no financial statements, no shareholder voting, no dividends, no management changes, no merger or acquisition information, nor any substantive financial data. It is a general corporate/operational update distributed via PR Newswire/EQS. As such, it does not fit any specialized financial or regulatory report category and falls under the fallback catch-all for miscellaneous regulatory announcements.
2026-06-04 English
关于参加2026年山东辖区上市公司投资者网上集体接待日活动的公告
Regulatory Filings Classification · 50% confidence The document is an announcement about the company’s participation in a regulator-organized online investor reception day event. It contains no financial statements, votes, or executive changes, nor does it present or attach a report. This type of general corporate/ regulatory disclosure falls under the fallback category “Regulatory Filings” (RNS).
2026-05-12 Chinese
关于向香港联交所递交H股发行并上市申请的进展公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement from a company about the progress of its application to issue H shares and list on the Hong Kong Stock Exchange. It mentions submission of application materials and provides links to the application documents on the exchange's website. The text explicitly states that this announcement is to inform domestic investors about the listing progress and that the application materials are draft versions subject to updates. There is no financial data, no detailed report content, and the document is relatively short (1083 characters). It is clearly an announcement about a capital market event (H-share issuance and listing application progress), not the actual issuance or financial report. Therefore, this fits best as a Capital/Financing Update (CAP) filing type, which covers updates on company fundraising and capital structure changes.
2026-05-07 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.